Forest partners with biotech and pharmaceutical companies around the world to develop and bring promising new medicines to market

Forest Laboratories's picture
Printer-friendly versionPrinter-friendly versionPDF versionPDF version
  • Joining Forest is an opportunity to become part of a forward-thinking community dedicated to helping improve patients' lives through medicine

On July 1, 2014, Actavis completed the acquisition of Forest Laboratories, creating one of the world’s fastest-growing specialty pharmaceutical companies. As a combined company, Actavis and Forest will invest more than $1 billion annually in the development of distinctive brand and generic products. This commitment is driven by one of the strongest development-focused R&D organizations in the industry, with an emphasis on strategic, innovative development of important durable products that will drive long-term value, and on being the partner of choice for new and existing development collaborations.

Partnership: The Building Blocks of Success

Our partnership-focused approach

Forest is a highly motivated and experienced partner with a long history of successful, high-value collaborations. Whether we’re working with small biotech firms, regional pharmaceutical companies, or multinational businesses, Forest’s commitment to flexibility and candor has helped us build lasting partner relationships that benefit patients and shareholders alike.

Today, Forest collaborates on clinically meaningful molecules that address important unmet needs. Our capabilities, expertise, and extensive network of relationships around the world allow us to take on opportunities in all stages of development and across therapeutic categories.

Establishing Forest in New Markets

Our successful partnership-focused business model has provided a solid foundation to reach markets around the world. Today, while Forest's commercial business is primarily U.S.-focused, our successful partnerships include companies based in Spain, Germany, France, Hungary, and more.

Forest has experience developing products on a worldwide scale. In 2012 alone, we enrolled more than 29,000 patients in clinical trials in 38 countries.

No matter how or where we operate, we are strategic and nimble in our pursuits. We invite you to get in touch with us to discuss partnership opportunities.

 

About Actavis + Forest

On July 1, 2014, Actavis (NYSE:ACT) completed the acquisition of Forest Laboratories, creating one of the world’s fastest-growing specialty pharmaceutical companies with annual revenues of more than $15 billion anticipated for 2015. The combination creates a Company with size and scale, a balanced offering of strong brands and generics, a focus on strategic, lower-risk drug development and a generic DNA, focused on cost efficiency across the expanded organization.

Careers

Join one of the world’s fastest-growing specialty pharmaceutical companies. The combination of Actavis + Forest is creating exciting career opportunities across our now larger and stronger global company. As we continue integrating our recruiting processes and systems, you may view career opportunities at the Actavis and Forest career sites.

© 2014 Forest Laboratories, Inc.       FRX16451   04/14

Thank you for visiting

You are now leaving the Forest Labs website. Forest Labs is not responsible for the accuracy, content, practices and standards of external sites.

Would you like to continue?

Yes

No

You are now leaving this site and will be directed to the Forest Europe corporate website.

Continue

Cancel

You are now leaving this site and will be directed to the Forest Canada corporate website.

Continue

Cancel

You are now leaving this site and will be directed to the Foundation Care Online Store.

Continue

Cancel

You are now leaving this site and will be directed to the Aptalis corporate website.

News Source : Forest partners with biotech and pharmaceutical companies around the world to develop and bring promising new medicines to market
Copy this html code to your website/blog to embed this press release.